Please wait while the formulary information is being retrieved.
GALAFOLD (migalastat HCl)
- Fabry disease
123 mg capsule
- 1 capsule (123 mg) by oral route every other day at the same time each day
Fabry disease
- 1 capsule (123 mg) by oral route every other day at the same time each day
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
GALAFOLD (migalastat HCl)
- Fabry disease
- None
- Headache disorder
More Frequent
Severe
Less Severe
- None
- Acute abdominal pain
- Constipation
- Depression
- Diarrhea
- Dizziness
- Dyspepsia
- Dyspnea
- Epistaxis
- Fatigue
- Fecal urgency
- Hypesthesia
- Muscle spasm
- Myalgias
- Nausea
- Pain
- Palpitations
- Paresthesia
- Proteinuria
- Pruritus of skin
- Skin rash
- Spasmodic torticollis
- Vertigo
- Weight gain
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Migalastat
No safety and efficacy data available age < 16 years.
- 1 Day – 16 Years
- No safety and efficacy data available age < 16 years.
Migalastat
- Severity Level:
2
- Additional Notes: Insufficient data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Migalastat
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Fabry disease | |
| E75.21 | Fabry (-anderson) disease |
| 0-9 | A-Z |
|---|---|
| E75.21 | Fabry (-anderson) disease |
Formulary Reference Tool